Why the study?
Neuregulin 4 (NRG4) has emerged as a candidate mediator of adipose-cardiovascular communication, but the evidence supporting its clinical relevance remains uneven.
Design
Narrative review
Answers are grounded in this paper and cite their sources.
NRG4 should not yet guide cardiovascular risk assessment or therapy; leaves open its biomarker potential pending prospective trials and standardized assays.
Neuregulin 4 (NRG4) has emerged as a candidate mediator of adipose–cardiovascular communication, but the evidence supporting its clinical relevance remains uneven. This narrative review reassesses NRG4 from a cardiovascular translational perspective using an author-defined five-level evidence-mapping hierarchy: Level 1, prospective or interventional human cardiovascular evidence; Level 2, human observational or genetic evidence; Level 3, cardiovascular-specific NRG4 experiments; Level 4, cross-tissue NRG4 mechanistic studies; and Level 5, canonical ErbB4 or downstream-pathway evidence without direct NRG4 validation. Cardiovascular-specific experiments support context-dependent effects of NRG4 on cardiac remodeling, autophagy, metabolic stress, ferroptosis, and acute ischemic injury. Recent preclinical work also implicates an NRG4–ErbB4/aryl hydrocarbon receptor (AHR)/cytochrome P450 1A1 (CYP1A1) axis linking brown adipose tissue (BAT) to the liver in experimental atherosclerosis. In contrast, human evidence is dominated by small observational studies, with limited prospective validation, uncertain assay comparability, and substantial metabolic confounding. Discordant human metabolic observations, receptor-isoform complexity, and the context-dependent oncologic biology of ErbB4 further constrain therapeutic interpretation. Circulating NRG4 may therefore be more informative as a state-dependent marker of adipose-organ communication than as a disease-specific cardiovascular biomarker. Reported discriminatory performance in individual cohorts should be regarded as exploratory and population-dependent rather than evidence of established diagnostic or prognostic utility. Clinical translation will require standardized assays, independent prospective cardiovascular cohorts, demonstration of incremental value beyond established metabolic and cardiovascular markers, human-relevant mechanistic models, direct target-engagement studies, and long-term safety evaluation.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: